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Objectives. The study objectives were l) to assess the long-term 
outcome of patients with biopsy-proved lymphocytic myoearditis 
(Dallas criteria), and 2) to compare the outcome of these patients 
with that of patients with idiopathic dilated cardiomyopathy. 
Background. Endomyocardial biopsy is frequently performed in
patients presenting with dilated cardiomyopathy to identify lym- 
phocytic myocarditis. Most previous tudies of the natural history. 
of myocarditis were performed before the establishment of the 
Dallas criteria. Thus, it is important to evaluate the prognostic 
value of positive endomyocardial biopsy findings in patients 
presenting with dilated cardiomyopathy, using standardized cri- 
teria for lymphocytic myocarditis. 
Methods. All endomyocardial biopsy results from the Mayo 
Clinic (October 1979 to April 1988) with a diagnosis of myocar- 
ditis were reclassified according to the Dallas criteria. Patients 
whose biopsy specimens showed borderline or lymphocytic myo- 
carditis were included in the study group; those with systemic 
inflammatory diseases known to be associated with myocardial 
involvement were excluded. Study group survival was compared 
with that for a cohort of patients with idiopathic dilated cardio- 
myopathy seen at the Mayo Clinic from 1976 to 1987 who had 
endomyoeardial biopsy findings negative for myocarditis. 
Results. Biopsy specimens from 41 patients met the Dallas 
criteria for a diagnosis of myocarditis (n = 28) or borderline 
myocarditis (n = 13). Of these 41 patients, 9 were excluded 
because of the presence of systemic diseases known to be associ- 
ated with myocarditis, and 5 patients were excluded because of 
lack of available follow-up data. The myocarditis tudy group 
therefore included 27 patients (10 with borderline myocarditis, 17 
with myocarditis). Fifty-eight patients with a diagnosis of idio- 
pathic dilated cardiomyopathy who underwent endomyocardial 
biopsy served as the comparison cohort. Ejection fraction 
was lower in patients with idiopathic dilated cardiomyopathy 
([mean .+ SD] 25 -+ 11%) than in those with myocarditis (38 -+ 
19%, p = 0.001), even though a higher proportion of myocarditis 
group patients were in New York Heart Association functional 
class III or IV (63%) than patients in the dilated cardiomyopathy 
group (30% p = 0.005). There was no difference in5-year survival 
rate between the myocarditis and idiopathic dilated cardiomyop- 
athy groups (56% vs. 54%, respectively). 
Conclusions. This study demonstrates that the long-term out- 
come of patients with biopsy-proved myocarditis seen in a referral 
setting is poor, although no different from that of patients with 
idiopathic dilated cardiomyopathy. With the current lack of 
proved effective treatment for lymphocytic myocarditis and no 
demonstration of survival benefit for patients with myocarditis, 
these data suggest hat endomyocardial biopsy performed to 
exclude myocarditis of limited prognostic value in the routine 
evaluation of dilated cardiomyopathy. 
(J Am Coil Cardiol 1995;26:80-4) 
Despite three decades of study, lymphocytic myocarditis re- 
mains an elusive clinical entity. The diagnosis of myocarditis i
challenging, and the reported prevalence has varied widely. 
The extent o which myocarditis a precursor of idiopathic 
dilated cardiomyopathy is uncertain but continues to be a 
subject of intense investigation. Furthermore, controlled trials 
demonstrating effective therapy for lymphocytic myocarditis 
are currently lacking. 
Most recent studies (1-4) suggest hat biopsy-proved myo- 
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carditis diagnosed according to the Dallas criteria is relatively 
uncommon in the United States. Natural history studies of 
myocarditis performed before the establishment of the Dallas 
criteria probably included patients not fulfilling the current 
histologic criteria (5-10). However, endomyocardial biopsy 
continues to be performed frequently in patients presenting 
with dilated cardiomyopathy in the belief that identifying 
lymphocytic myocarditis will have prognostic value or thera- 
peutic implications. 
]'he purpose of the present study was 1) to assess the 
long-term outcome of patients with biopsy-proved lymphocytic 
myocarditis diagnosed according to the Dallas criteria, and 2) 
to compare the outcome of patients with myocarditis with that 
of patients with idiopathic dilated cardiomyopathy who had 
negative ndomyocardial biopsy findings for lymphocytic myo- 
carditis. 
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Methods 
Permission to conduct his study was granted by, the Insti- 
tutional Review Board of Mayo Foundation. All endomyocar- 
dial biopsies performed at the Mayo Clinic from October 1979 
to April 1988 with a diagnosis of myocarditis were reviewed 
and classified according to the Dallas criteria. 
Patients. Patients whose biopsy findings met the criteria 
for borderline or definite lymphocytic myocarditis were in- 
cluded in the study. Patients with systemic inflammatory 
diseases known to be associated with myocardial involvement 
and patients without available follow-up were excluded. 
Patients with lymphocytic myocarditis were compared with 
a cohort of patients with idiopathic dilated cardiomyopathy 
seen at the Mayo Clinic from 1976 to 1987 who had negative 
endomyocardial findings for myocarditis according to the 
Dallas criteria. Idiopathic dilated cardiomyopathy was defined 
as global left ventricular dilatation with impaired systolic 
function, with or without overt heart failure, occurring in the 
absence of a known cardiac or systemic ause. Patients were 
excluded from the idiopathic dilated cardiomyopathy group if 
they demonstrated evidence of uncontrolled hypertension, 
history of myocardial infarction or coronary artery disease with 
->40% stenosis of one or more epicardial coronary arteries by 
coronary angiography. 
In both groups of patients, the medical record was reviewed 
for clinical details at the time of diagnosis. Data recorded 
included age, gender, duration of heart failure symptoms, New 
York Heart Association functional class, history of viral illness 
within the 3 months preceding diagnosis, pregnancy within 12 
months of diagnosis, family history of cardiomyopathy and 
excessive alcohol consumption (>4 fl oz [120 ml] of alcohol/ 
day or frequent binge drinking). For patients in the myocarditis 
group the use of immunosuppressive therapy was also re- 
corded. 
Left ventricular function. Evaluation of left ventricular 
function was determined by radionuclide angiography, two- 
dimensional and M-mode echocardiography or contrast left 
ventriculography. When more than one modality was utilized 
in a single patient, he rank order of preference for assessment 
of ejection fraction was 1) radionuclide angiography; 2)echo- 
cardiography; 3)contrast left ventriculography. Left ventricu- 
lar systolic dysfunction was defined as an ejection fraction 
<50%. 
Endomyocardial biopsy. Endomyocardial biopsy speci- 
mens were obtained from the right ventricular septum using 
standard techniques, and all were reviewed by a single exam- 
iner (W.D.E.) and classified according to the Dallas criteria as 
positive for lymphocytic myocarditis, positive for borderline 
lymphocytic myocarditis or negative for myocarditis (10). 
Follow-up. Follow-up information was obtained from the 
Mayo Clinic medical record, by mailed questionnaire and by 
telephone follow-up, if necessary. Questionnaires were mailed 
to all patients not already known to have died on the basis of 
the Mayo Clinic medical record. For deceased patients, the 
date of death or cardiac transplantation (considered as death) 
was recorded; no effort was made to determine the cause of 
death. Current medications at the time of follow-up were 
recorded. 
Statistical analysis. Group comparisons of the baseline 
characteristics of the myocarditis and idiopathic dilated car- 
diomyopathy groups were based on the chi-square test of 
proportions for dichotomous variables and the two-sample t 
test for continuous variables. Cumulative survival was esti- 
mated by the method of Kaplan-Meier, and the myocarditis 
and idiopathic dilated cardiomyopathy curves, overall and 
within subgroups, were compared by the log rank test. Statis- 
tical significance was judged at the p < 0.05 level. 
Results  
Myocarditis. From October 1979 to April 1988 a total of 
850 endomyocardial biopsies were performed at the Mayo 
Clinic (excluding biopsies of cardiac allografts). The specified 
clinical indications for biopsy consisted of unexplained heart 
failure or dilated cardiomyopathy (53%), possible myocarditis 
(16%), possible amyloidosis (7%), restrictive cardiomyopathy 
(4%), ventricular dysrhythmia (6%), sarcoidosis (2%), eosino- 
philic syndrome (2%), ischemic heart disease (2%), possible 
constrictive pericarditis (2%) and miscellaneous (6%). Among 
56 patients originally diagnosed as having myocarditis, 41 met 
the Dallas criteria for a diagnosis of myocarditis (n = 28) or 
borderline myocarditis (n = 13), and 15 did not. From these 41 
patients, 9 (7 with myocarditis, 2 with borderline myocarditis) 
were excluded because of the presence of systemic inflamma- 
tory diseases known to be associated with myocarditis (3 with 
sarcoidosis; 2 with undifferentiated connective tissue disease; 
and 1 each with scleroderma, polymyositis, ystemic lupus 
erythematosis and systemic streptococcal infection). Five pa- 
tients were excluded because of lack of follow-up. After 
exclusions, the study group included 27 patients with myocar- 
ditis (n = 17) or borderline myocarditis (n = 10). 
Dilated eardiomyopathy. From 1976 to 1987, 222 patients 
seen at the Mayo Clinic met the criteria for a diagnosis of 
idiopathic dilated cardiomyopathy (11). Of these, 58 patients 
underwent cndomyocardial biopsy performed at this institu- 
tion and served as the idiopathic dilated cardiomyopathy 
cohort for comparison with the myocarditis group. The endom- 
yocardial biopsy specimens of these 58 patients were all 
reviewed by a single examiner (W.D.E.) and were considered 
to be negative for myocarditis according to the Dallas criteria. 
Age, gender, family history of cardiomyopathy and preg- 
nancy history were not significantly different between the 
myocarditis and idiopathic dilated cardiomyopathy groups 
(Table 1). The myocarditis group had a higher prevalence of 
viral illness within the 3 months before biopsy (40% vs. 19%, 
p -- 0.03), a higher proportion of patients with excessive 
alcohol intake (22% vs. 7%, p = (t.04) and a higher proportion 
of patients in functional class III or IV (63% vs. 30%, p = 
0.005). Ejection fraction, however, was significantly lower in 
the idiopathic dilated cardiomyopathy group (25 _+ 11%) than 
in the myocarditis group (38 +_ 19%, p = 0.001). Therefore, 
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Table 1. Comparison of Clinical Features of Patients With 
Myocarditis and Idiopathic Dilated Cardiomyopathy 
MC IDCM 
(n = 27) (n = 58) p Value 
Age (yr) 47 _+ 17 48 _+ 12 0.67 
Male gender (%) 16 (59%) 42 (72%) 0.23 
NYHA functional class III 17 (63%) 16 (30%) 0.005 
or IV 
Viral syndrome history 11 (40%) 11 (19%) 0.03 
History of excessive alcohol 6 (22%) 4 (7%) 0.04 
consumption 
Recent pregnancy 1 (4%) 2 (3%) 0.95 
Family history of 2 (7%) 5 (9%) 0.85 
cardiomyopathy 
Baseline ejection fraction 38 + 19 25 -+ 11 0.001 
(%) 
Data presented are mean value 
idiopathic dilated cardiomyopathy; 
Heart Association. 
-+ SD or number (%) of patients. IDCM : 
MC = myocarditis; NYHA = New York 
there appeared to be a group of patients with myocarditis with 
a preserved ejection fraction but (by definition) no such group 
in those with idiopathic dilated cardiomyopathy. Despite this 
difference in ejection fraction, symptoms were worse in the 
myocarditis group. 
The median interval from onset of symptoms to diagnosis 
was 3.5 months in the myocarditis group and 7.4 months in the 
idiopathic dilated cardiomyopathy group (p = 0.12). Mean 
follow-up in years was similar for both groups (4.7 _ 2.7 for the 
myocarditis group vs. 4.4 _ 3 for the idiopathic dilated 
cardiomyopathy group). Medications at the time of follow-up 
(Table 2) were similar with the exception of digoxin (more 
common in idiopathic dilated cardiomyopathy) and antiar- 
rhythmic therapy (more common in myocarditis). 
Survival. There was no significant difference between the 
two groups in overall survival: The 5-year survival rate was 
56% in the myocarditis group and 54% in the dilated cardio- 
myopathy group (Fig. 1). When analyzed separately according 
to the diagnosis of myocarditis, borderline myocarditis and 
idiopathic dilated cardiomyopathy, there were also no signifi- 
cant differences in overall survival (Fig. 2). Although the 
borderline myocarditis group demonstrated a trend toward 
Table 2. Comparison of Medication at Follow-Up for Patients With 
Myocarditis and Idiopathic Dilated Cardiomyopathy 
MC IDCM p Value 
Follow-up (yr) 4.7 _+ 2.7 4.4 _+ 3.0 0.66 
Medications 
Digoxin 1 (8%) 20 (74%) 0.001 
Diuretic drugs 4 (31%) 16 (59%) 0.09 
Vasodilators 5 (39%) 18 (67%) 0.09 
Coumadin 3 (23%) 12 (44%) 0.19 
Aspirin 0 (0%) 3 (11%) 0.21 
Antiarrhythmic agents 6 (46%) 4 (15%) 0.03 
Data presented are mean value ~ SD or number (%) of patients. Abbrevi- 
ations as in Table 1. 
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Figure 1. Survival of patients with biopsy-proved myocarditis (definite 
or borderline) compared with that for patients with idiopathic dilated 
cardiomyopathy (IDCM) and negative endomyocardial biopsy find- 
ings. 
decreased survival compared with the other two groups, the 
number of patients is small, and firm conclusions cannot be 
drawn. Seven patients in the myocarditis group were treated 
with immunosuppressive therapy at the discretion of their 
physician; three of these seven patients (43%) were alive at 
follow-up, a proportion similar to patients treated without 
immunosuppressive therapy. 
D iscuss ion  
The reported prevalence of lymphocytic myocarditis in 
biopsy series has varied widely. The frequency of myocarditis 
in patients presenting with dilated cardiomyopathy has ranged 
from as low as 0% to as high as 89% (5,12-19). The wide range 
of estimates most likely has several causes. In addition to 
changing histologic criteria, the frequency of lymphocytic 
myocarditis may be related to the acuity of heart failure in the 
population under study, to institutional referral patterns, to 
sporadic viral epidemics and to the clinical threshold for 
performing endocardial biopsy in patients presenting with 
congestive heart failure, systolic dysfunction and normal cor- 
onary arteries (3). Recent reports (1-4) since the establish- 
ment of the Dallas criteria, however, have demonstrated a
Figure 2. Survival of patients with biopsy-proved myocarditis (MC) 
compared with that for patients with borderline myocarditis and 
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more consistent frequency of myocarditis, ranging from 4% to 
10% in referral series. The potential prognostic or therapeutic 
value of establishing the diagnosis of myocarditis may account 
for the continued use of endomyocardial biopsy in patients 
presenting with acute congestive heart failure despite recent 
reports questioning the clinical utility of the procedure (20-23). 
The results of the present study confirm that biopsy-proved 
lymphocytic myocarditis diagnosed according to the Dallas 
criteria is indeed uncommon. Specifically, during an 8-year 
time period, only 28 biopsy findings in our institution met the 
Dallas criteria for definite and 13 for borderline myocarditis. 
These represented 3.2% and 1.5%, respectively, of the total of 
850 endomyocardial biopsies (excluding biopsies from al- 
lografts) performed at this institution during that time period; 
they were 4.8% and 2.2%, respectively, of the 587 biopsies 
performed to evaluate idiopathic heart failure. Of the 41 
patients, 9were found to have systemic diseases known to be 
associated with myocarditis, thus further educing the biopsy 
frequency of idiopathic lymphocytic myocarditis. 
Some have suggested that previous myocarditis a com- 
mon cause of dilated cardiomyopathy (9) and that spontaneous 
recovery from unexplained heart failure indicates myocarditis 
rather than cardiomyopathy as the underlying disease process 
(8). However, spontaneous improvement in ventricular func- 
tion has also been observed inpatients without biopsy evidence 
of myocarditis (1,13). The long-term prognosis of small groups 
of patients presenting with clinical features uggesting viral 
myocarditis (but without biopsy confirmation) has been re- 
ported to be good (6,7,20). In a series of patients with 
biopsy-proved lymphocytic myocarditis by the Dallas Criteria, 
the 3-year survival rate has been reported to be 83% (21). Our 
data confirm and extend this observation toa larger group with 
a longer follow-up. 
Findings in the current study suggest hat patients with 
biopsy-proved myocarditis diagnosed according to the Dallas 
criteria do not demonstrate a different survival compared with 
those with idiopathic dilated cardiomyopathy and negative 
endomyocardial biopsy findings. Patients with borderline myo- 
carditis showed a trend toward decreased survival compared 
with those with definite myocarditis. However, the small 
number of patients with borderline myocarditis makes it 
difficult to draw meaningful conclusions about survival in this 
group. Some investigators (2) have suggested that patients with 
borderline myocarditis may respond more favorably to immu- 
nosuppressive treatment and may perhaps represent a separate 
pathologic entity. Others, however, have reported (24) a high 
percent of positivity for myocarditis on repeat biopsy in 
patients whose first biopsy demonstrated only borderline myo- 
carditis. The distinction between definite and borderline myo- 
carditis may be further confounded by the sampling error 
known to be associated with the endomyocardial biopsy tech- 
nique (25). 
The current study showed no survival difference between 
patients with biopsy-proved myocarditis and dilated cardio- 
myopathy with negative biopsy findings and may also be viewed 
within the context of previous tudies of the clinical course of 
dilated cardiomyopathy from this institution. Although there 
was referral bias inherent in both the myocarditis and idio- 
pathic dilated cardiomyopathy populations (26), there was also 
no difference in survival of patients with idiopathic dilated 
cardiomyopathy who had, or did not have, an endomyocardial 
biopsy (11). 
Diagnostic riteria. The diagnosis of myocarditis remains 
challenging. The Dallas criteria were established for the pur- 
pose of defining a working classification of myocarditis primar- 
ily for consistency in the National Heart, Lung, and Blood 
Institute-funded Multi-Center Myocarditis Trial (4). The Dal- 
las criteria were not intended to be used as a sine qua non for 
the histologic diagnosis of myocarditis, and the investigators 
specifically stated that "histology itself may prove not to be the 
gold standard" for the diagnosis of myocarditis (10,27). The 
problems of sampling error as well as timing of biopsy in 
relation to onset of symptoms continues to make the role of 
myocarditis n the etiology of idiopathic dilated cardiomyopa- 
thy difficult to determine (15). Furthermore, ven among the 
investigators who developed the Dallas classification, some 
discordance in biopsy interpretation may occur (28). One-third 
of the patients entered in the Multi-Center Myocarditis Trial 
on the basis of interpretation f the biopsy tissues by the local 
pathologist were considered by the study panel of cardiac 
pathologists to have negative findings for myocarditis (28). 
Nevertheless, other more sensitive and specific analytic 
techniques are not widely available at this time for the 
diagnosis of lymphocytic myocarditis by endomyocardial bi-
opsy. It may be that the evolution of more effective diagnostic 
methodology will permit more accurate identification of lym- 
phocytic myocarditis in the future. Similarly, more specific 
therapy, coupled with more accurate diagnosis, may result in 
improved survival for patients with lymphocytic myocarditis. 
Limitations of the study. It should be noted that the 
present study was limited to idiopathic lymphocytic endocar- 
ditis. Patients with giant-cell myocarditis, eosinophilic myocar- 
ditis, sarcoidosis or secondary forms of lymphocytic myocardi- 
tis (e.g., those associated with multisystem inflammatory 
disorders) may represent a different pathophysiology and have 
different long-term outcomes. Insofar as some of these other 
forms of myocarditis are treatable or have a different progno- 
sis, the endomyocardial biopsy may be of clinical utility. 
Summary and future directions. To our knowledge, the 
present study represents he longest follow-up period of pa- 
tients with lymphocytic myocarditis diagnosed inbiopsy tissues 
according to the Dallas criteria. It demonstrates that the 6-year 
survival of patients with biopsy-proved lymphocytic myocardi- 
tis seen in a referral setting is seriously compromised, although 
no different from that of patients with idiopathic dilated 
cardiomyopathy. Our study highlights the limitations of the 
conventionally analyzed endomyocardial biopsy in the evalua- 
tion of patients presenting with dilated cardiomyopathy. Fur- 
ther studies will need to be directed toward eveloping analytic 
techniques that enhance the prognostic and diagnostic utility 
of the endomyocardial biopsy. Furthermore, until effective 
therapy for lymphocytic myocarditis clearly established, the 
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value of establishing this diagnosis by endomyocardial biopsy 
will remain low. 
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